Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Prior history of varicella (chickenpox) or residence in a country with endemic varicella zoster virus infection for at least 30 years~* Temperature less than 100.4 °F on day of vaccination~* Female participants of reproductive potential must have a negative pregnancy test and agree to remain abstinent or use two acceptable contraceptive methods for 3 months postvaccination~* In good health~Exclusion Criteria:~* History of hypersensitivity reaction to any vaccine component, including gelatin or neomycin~* Household exposure to pregnant women who have not had chickenpox and have not been vaccinated against varicella or to immunosuppressed/immunodeficient individuals~* Household or workplace exposure to children 18 months and younger who have not been vaccinated against varicella~* Prior history of herpes zoster~* Prior receipt of any varicella or zoster vaccine~* Received or is expected to receive immune globulin and/or blood products from 5 months prior to randomization through 42 days after vaccination~* On immunosuppressive therapy~* Known or suspected immune dysfunction~* Received a live virus vaccine or is scheduled to receive a live virus vaccine from 4 weeks prior to study vaccination through the completion of all study visits~* Received any inactivated vaccine or is scheduled to receive any inactivated vaccine from 7 days prior to study vaccination through 7 days postvaccination, except for inactivated influenza vaccine~* Not ambulatory~* Pregnant or breastfeeding~* Use of nontopical antiviral therapy with activity against herpes viruses~* Active untreated tuberculosis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Full Dose Subcutaneous (Type: ACTIVE_COMPARATOR): Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
- 1/3 Dose Subcutaneous (Type: EXPERIMENTAL): Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
- Full Dose Intradermal (Type: EXPERIMENTAL): Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
- 1/3 Dose Intradermal (Type: EXPERIMENTAL): Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
- 1/10 Dose Intradermal (Type: EXPERIMENTAL): Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
- 1/27 Dose Intradermal (Type: EXPERIMENTAL): Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).